-
Mashup Score: 0
Uproleselan plus chemotherapy did not demonstrate clinical benefit over chemotherapy alone, though did show an acceptable safety profile.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable residual disease (AML-MR) by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The @OncBrothers and @beatalleukemia discuss how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating AML-MR by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes. #leusm https://t.co/ZYKCSzNhSJ
-
-
Mashup Score: 0
Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Eytan M. Stein, MD (@Doctor_E_Stein), of @MSKCancerCenter, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia. #leusm https://t.co/4EwJcPx9NI
-
-
Mashup Score: 5
Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia @MSKCancerCenter #leusm https://t.co/z04LppFhyn
-
-
Mashup Score: 195How I treat refractory and relapsed acute myeloid leukemia - 12 day(s) ago
Using a series of 3 illustrative cases, Thol and colleagues discuss their approach to relapsed/refractory acute myeloid leukemia. Although allogeneic hemat
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
How I treat refractory and relapsed acute myeloid leukemia https://t.co/g3WqzWWRH2 #leusm https://t.co/46d6B1L3HK
-
-
Mashup Score: 5
Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia @MSKCancerCenter #leusm https://t.co/z04LppFhyn
-
-
Mashup Score: 9
Join us for a free webinar covering the latest information for patients and caregivers. To register by phone, call (877) 264-4949. Topics Covered We invite you to learn more about: Current and emerging therapies for hairy cell leukemia (HCL) Treatment for relapsed/refractory HCL Side-effect management Advocating for quality-of-life concerns Speaker Leslie A. Andritsos, MD Professor of Internal Medicine Division of Hematology/ Oncology University of New Mexico Comprehensive Cancer Center Albuquerque, NM Submit a question for Dr. Andritsos to answer during the Q&A session. Program Support Support for this program provided by Genentech, a member of the Roche Group. < Back to Webcasts
Source: lls.orgCategories: General Medicine News, Partners & KOLsTweet-
Expert advice on the future of hairy cell leukemia (HCL) care is just a click away! 🖱️🎧 Join Dr. Leslie A. Andritsos of @UNMCCC on Dec. 19 at 1 PM ET to explore the latest advancements. Register now 👉 https://t.co/dAevjP5I6h #leusm https://t.co/7sTCoRiPix
-
-
Mashup Score: 5
Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia @MSKCancerCenter #leusm https://t.co/z04LppFhyn
-
-
Mashup Score: 0
The therapeutic arsenal for patients with ALL in the first line and beyond is expanding beyond traditional approaches, enabling better outcomes for patients.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ALL Treatment Paradigm Displays Significant Gains as @NCCN Guidelines Evolve @MDAndersonNews #leusm https://t.co/7iMR9jzsIF
-
-
Mashup Score: 1Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML - 24 day(s) ago
Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML @GCC_Cortes @GACancerCenter #leusm https://t.co/nkGKHVOSZN
-
A randomized, double-blind, phase 3 bridging trial conducted in China evaluating uproleselan plus chemotherapy in patients with relapsed/refractory acute myeloid leukemia failed to meet its primary end point of overall survival. #leusm https://t.co/UnNLfJdfjO